Ameriprise Financial Inc. lifted its position in Heska Corp (NASDAQ:HSKA) by 10.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 48,209 shares of the medical research company’s stock after acquiring an additional 4,691 shares during the period. Ameriprise Financial Inc. owned approximately 0.67% of Heska worth $4,247,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Royal Bank of Canada raised its holdings in Heska by 96.9% during the 2nd quarter. Royal Bank of Canada now owns 1,014 shares of the medical research company’s stock worth $103,000 after buying an additional 499 shares during the period. SG Americas Securities LLC acquired a new stake in Heska during the 3rd quarter worth approximately $108,000. Victory Capital Management Inc. raised its holdings in Heska by 17.5% during the 2nd quarter. Victory Capital Management Inc. now owns 1,133 shares of the medical research company’s stock worth $116,000 after buying an additional 169 shares during the period. Municipal Employees Retirement System of Michigan acquired a new stake in Heska during the 2nd quarter worth approximately $154,000. Finally, BNP Paribas Arbitrage SA raised its holdings in Heska by 59.2% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 1,858 shares of the medical research company’s stock worth $190,000 after buying an additional 691 shares during the period. Institutional investors and hedge funds own 80.89% of the company’s stock.
Several analysts have commented on HSKA shares. Raymond James Financial restated a “buy” rating on shares of Heska in a report on Monday, December 4th. B. Riley dropped their target price on shares of Heska from $96.50 to $93.00 and set a “neutral” rating on the stock in a report on Friday, November 3rd. BidaskClub upgraded shares of Heska from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. Aegis restated a “buy” rating on shares of Heska in a report on Tuesday, December 19th. Finally, Zacks Investment Research downgraded shares of Heska from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $113.30.
Heska Corp (HSKA) opened at $80.21 on Monday. The firm has a market cap of $581.03, a P/E ratio of 41.99, a PEG ratio of 2.14 and a beta of 0.75. Heska Corp has a 52 week low of $70.49 and a 52 week high of $115.00.
Heska (NASDAQ:HSKA) last issued its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.03. The company had revenue of $31.40 million during the quarter, compared to analysts’ expectations of $36.10 million. Heska had a net margin of 10.67% and a return on equity of 15.35%. The business’s quarterly revenue was down 6.0% on a year-over-year basis. During the same period last year, the business earned $0.45 EPS. equities analysts predict that Heska Corp will post 2.03 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Ameriprise Financial Inc. Has $4.25 Million Position in Heska Corp (HSKA)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.com-unik.info/2018/01/01/ameriprise-financial-inc-has-4-25-million-position-in-heska-corp-hska.html.
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corp (NASDAQ:HSKA).
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.